Exact Sciences (EXAS) Lower on Negative Blog Post
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St set for tepid open as oil prices fall, Treasury yields rise
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Exact Sciences Corp (EXAS) Misses Q2 EPS by 1c
July 23, 2013 7:31 AM EDTExact Sciences Corp (NASDAQ: EXAS) reported Q2 EPS of ($0.19), $0.01 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.02 million.
"With the completion of Exact's submission to the FDA for Cologuard, our colorectal... More
